Affiliated to research
2015/2016 - R&D trainee, focus on dementia and diabetes mellitus
2016 - Graduated from Charles University in Prague as medical doctor (M.D.)
2016 - Admitted to doctoral studies at Karolinska Institutet
There is lack of high-quality evidence for pharmacological care in dementia, especially in multimorbid patients. Moreover dementia patients are prescribed significant number of chronic medication with high chance of interactions and side effects. Using large unrestricted Swedish cohorts can provide good evidence on which medication should be used and which omitted in this understudied population. My work revolves around high-risk patients diagnosed with different dementia disorders and diabetes. Linking the data from the Swedish Dementia Registry with other registers provides high-quality information on antidiabetic, dementia, cardiovascular and psychotropic medication and their associations with mortality rates, incidence of stroke, cardiovascular events and cognitive decline. In addition, with the help of data on dementia-free controls we can assess the changes in clinical care made in connection to dementia diagnosis and assess their efficacy.
Diabetes is associated with significantly higher risk of dementia, therefore proper diabetes management and biochemical control (e.g. glucose levels, HbA1c) is the cornerstone of dementia prevention in this cohort. We collaborate with the large AMORIS study (~800,000 subjects) started in the 1980's and 1990's, which provides data on baseline and repeated blood biochemistry measurements taken as part of the health check-ups with the possibility to follow-up patients using the linkages with other registers. AMORIS gives a unique opportunity to study long-term changes in blood biochemistry prior to dementia in a massive cohort.
Overall aims of my PhD project:
1. Finding beneficial and detrimental pharmacological treatments in patients with diabetes mellitus and dementia.
Focus on: - antidiabetic, dementia, cardiovascular and psychotropic medication - changes in pharmacological care before and after dementia diagnosis - differences in mortality, stroke, myocardial infarction, cognitive decline associated with the use of specific medication
2. Determining how the metabolic changes in mid-life contribute to risk of dementia.
Focus on: - changes in blood glucose, lipid and inflammatory biochemistry associated with different dementia diagnoses - long-term biochemical trajectories in the lead up to dementia diagnosis
Keywords: Clinical epidemiology, pharmacoepidemiology, diabetes, dementia
Co-supervisor to master students:
2016/2017 - Pontus Dannberg (Medicine)
2017/2018 - Abbe Ulgrén (Biomedicine)
2018 - Oliver Edner (Medicine)
2018 - Hugo Söderström (Medicine)
2019 - Sofia Lim (Medicine)
2019 - Filippa Martinsson (Medicine)
2020 - Ramin Sasani (Medicine)
2020 - Sara Fadhil (Medicine)
Co-supervisor to medical doctors:
2017 - Hamsah Al-Qashqri